Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

MicroRNA 21 Emerging Role in Diabetic Complications: A Critical Update

Author(s): Dipayan Roy, Anupama Modi, Manoj Khokhar, Shrimanjunath Sankanagoudar, Dharamveer Yadav, Shailja Sharma, Purvi Purohit* and Praveen Sharma

Volume 17, Issue 2, 2021

Published on: 02 May, 2020

Page: [122 - 135] Pages: 14

DOI: 10.2174/1573399816666200503035035

Price: $65

TIMBC 2025
Abstract

Background: Diabetes Mellitus is a multifactorial disease encompassing various pathogenic pathways. To avoid morbidity and mortality related to diabetic complications, early detection of disease complications as well as targeted therapeutic strategies are essential.

Introduction: MicroRNAs (miRs) are short non-coding RNA molecules that regulate eukaryotic posttranscriptional gene expression. MicroRNA-21 has diverse gene regulatory functions and plays a significant role in various complications of Type 2 diabetes mellitus (T2DM).

Methods: The study included electronic database searches on Pubmed, Embase, and Web of Science with the search items MicroRNA21 and each of the diabetic complications. The search was carried out up to November, 2019.

Results: MicroRNA-21 modulates diabetic cardiomyopathy by affecting vascular smooth muscle cell proliferation and apoptosis, cardiac cell growth and death, and cardiac fibroblast functions. At the renal tubules, miR-21 can regulate the mesangial expansion, interstitial fibrosis, macrophage infiltration, podocyte loss, albuminuria and fibrotic and inflammatory gene expression related to diabetic nephropathy. Overexpression of miR-21 has been seen to play a pivotal role in the pathogenesis of diabetic retinopathy by contributing to diabetes-induced endothelial dysfunction as well as low-grade inflammation.

Conclusion: Considering the raised levels of miR-21 in various diabetic complications, it may prove to be a candidate biomarker for diabetic complications. Further, miR-21 antagonists have shown great potential in the treatment of diabetic cardiomyopathy, diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy related complications in the future. The current review is the first of its kind encompassing the roles miR-21 plays in various diabetic complications, with a critical discussion of its future potential role as a biomarker and therapeutic target.

Keywords: Type 2 diabetes mellitus, MicroRNA-21, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic neuropathy.

[1]
International Diabetes Federation. IDF Diabetes Atlas 8th edn Brussels, Belgium: International Diabetes Federation, 2017.http://www.diabetesatlas.org
[2]
Chien H-Y, Lee T-P, Chen C-Y, et al. Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications. J Chin Med Assoc 2015; 78(4): 204-11.
[http://dx.doi.org/10.1016/j.jcma.2014.11.002] [PMID: 25529478]
[3]
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9(2): 102-14.
[http://dx.doi.org/10.1038/nrg2290] [PMID: 18197166]
[4]
Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11(4): 252-63.
[http://dx.doi.org/10.1038/nrm2868] [PMID: 20216554]
[5]
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]
[6]
McClelland AD, Kantharidis P. microRNA in the development of diabetic complications. Clin Sci (Lond) 2014; 126(2): 95-110.
[http://dx.doi.org/10.1042/CS20130079] [PMID: 24059587]
[7]
Barutta F, Bellini S, Mastrocola R, Bruno G, Gruden G. MicroRNA and Microvascular Complications of Diabetes. Int J Endocrinol 2018.20186890501
[http://dx.doi.org/10.1155/2018/6890501] [PMID: 29707000]
[8]
Zeng J, Xiong Y, Li G, et al. MiR-21 is overexpressed in response to high glucose and protects endothelial cells from apoptosis. Exp Clin Endocrinol Diabetes 2013; 121(7): 425-30.
[http://dx.doi.org/10.1055/s-0033-1345169] [PMID: 23771797]
[9]
Sekar D, Venugopal B, Sekar P, Ramalingam K. Role of microRNA 21 in diabetes and associated/related diseases. Gene 2016; 582(1): 14-8.
[http://dx.doi.org/10.1016/j.gene.2016.01.039] [PMID: 26826461]
[10]
Osipova J, Fischer D-C, Dangwal S, et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metab 2014; 99(9): E1661-5.
[http://dx.doi.org/10.1210/jc.2013-3868] [PMID: 24937532]
[11]
Chakraborty C, George Priya Doss C, Bandyopadhyay S. miRNAs in insulin resistance and diabetes-associated pancreatic cancer: the ‘minute and miracle’ molecule moving as a monitor in the ‘genomic galaxy’. Curr Drug Targets 2013; 14(10): 1110-7.
[http://dx.doi.org/10.2174/13894501113149990182] [PMID: 23834149]
[12]
Meng S, Cao J, Zhang X, et al. Downregulation of MicroRNA- 130a contributes to endothelial progenitor cell dysfunction in diabetic patients via Its target Runx3.PLoS ONE. 2013; 8: 12(7): e68611.
[http://dx.doi.org/10.1371/journal.pone.0068611]
[13]
De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 diabetes mellitus and cardiovascular disease: Genetic and Epigenetic Links. Front Endocrinol (Lausanne) 2018; 9: 2.
[http://dx.doi.org/10.3389/fendo.2018.00002] [PMID: 29387042]
[14]
Dai B, Li H, Fan J, et al. MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin. Cardiovasc Diabetol 2018; 17(1): 123.
[http://dx.doi.org/10.1186/s12933-018-0767-z] [PMID: 30180843]
[15]
Liu S, Li W, Xu M, Huang H, Wang J, Chen X. Micro-RNA 21Targets dual specific phosphatase 8 to promote collagen synthesis in high glucose-treated primary cardiac fibroblasts. Can J Cardiol 2014; 30(12): 1689-99.
[http://dx.doi.org/10.1016/j.cjca.2014.07.747] [PMID: 25418215]
[16]
Shen E, Diao X, Wang X, Chen R, Hu B. MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol 2011; 179(2): 639-50.
[http://dx.doi.org/10.1016/j.ajpath.2011.04.034] [PMID: 21704010]
[17]
Al-Hayali MA, Sozer V, Durmus S, et al. Clinical Value of Circulating Microribonucleic Acids miR-1 and miR-21 in Evaluating the Diagnosis of Acute Heart Failure in Asymptomatic Type 2 Diabetic Patients. Biomolecules 2019; 9(5): 193.
[http://dx.doi.org/10.3390/biom9050193] [PMID: 31109008]
[18]
Guo R, Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. Biochim Biophys Acta Mol Basis Dis 2017; 1863(8): 2070-7.
[http://dx.doi.org/10.1016/j.bbadis.2017.03.013] [PMID: 28344129]
[19]
Wang J, Duan L, Gao Y, et al. Angiotensin II receptor blocker valsartan ameliorates cardiac fibrosis partly by inhibiting miR-21 expression in diabetic nephropathy mice. Mol Cell Endocrinol 2018; 472(472): 149-58.
[http://dx.doi.org/10.1016/j.mce.2017.12.005] [PMID: 29233785]
[20]
La Sala L, Mrakic-Sposta S, Micheloni S, Prattichizzo F, Ceriello A. Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. Cardiovasc Diabetol 2018; 17(1): 105.
[http://dx.doi.org/10.1186/s12933-018-0748-2] [PMID: 30037352]
[21]
Gao L, Liu Y, Guo S, et al. LAZ3 protects cardiac remodeling in diabetic cardiomyopathy via regulating miR-21/PPARa signaling. Biochim Biophys Acta Mol Basis Dis 2018; 1864(10): 3322-38.
[http://dx.doi.org/10.1016/j.bbadis.2018.07.019] [PMID: 30031228]
[22]
Yildirim SS, Akman D, Catalucci D, Turan B. Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1. Cell Biochem Biophys 2013; 67(3): 1397-408.
[http://dx.doi.org/10.1007/s12013-013-9672-y] [PMID: 23723006]
[23]
Li Q, Yao Y, Shi S, et al. Inhibition of miR-21 alleviated cardiac perivascular fibrosis via repressing EndMT in T1DM. J Cell Mol Med 2020; 24(1): 910-20.
[http://dx.doi.org/10.1111/jcmm.14800] [PMID: 31680453]
[24]
Hathaway QA, Pinti MV, Durr AJ, Waris S, Shepherd DL, Hollander JM. Regulating microRNA expression: at the heart of diabetes mellitus and the mitochondrion. Am J Physiol Heart Circ Physiol 2018; 314(2): H293-310.
[http://dx.doi.org/10.1152/ajpheart.00520.2017] [PMID: 28986361]
[25]
Seeger T, Fischer A, Muhly-Reinholz M, Zeiher AM, Dimmeler S. Long-term inhibition of miR-21 leads to reduction of obesity in db/db mice. Obesity (Silver Spring) 2014; 22(11): 2352-60.
[http://dx.doi.org/10.1002/oby.20852] [PMID: 25141837]
[26]
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010; 376(9735): 124-36.
[http://dx.doi.org/10.1016/S0140-6736(09)62124-3] [PMID: 20580421]
[27]
Merrigan SL, Kennedy BN. Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF. Br J Pharmacol 2017; 174(16): 2636-51.
[http://dx.doi.org/10.1111/bph.13875] [PMID: 28547797]
[28]
Reynolds AL, Alvarez Y, Sasore T, et al. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. J Biol Chem 2016; 291(14): 7242-55.
[http://dx.doi.org/10.1074/jbc.M115.710665] [PMID: 26846851]
[29]
Agrawal S, Chaqour B. MicroRNA signature and function in retinal neovascularization. World J Biol Chem 2014; 5(1): 1-11.
[http://dx.doi.org/10.4331/wjbc.v5.i1.1] [PMID: 24600510]
[30]
Guduric-Fuchs J, O’Connor A, Cullen A, et al. Deep sequencing reveals predominant expression of miR-21 amongst the small non-coding RNAs in retinal microvascular endothelial cells. J Cell Biochem 2012; 113(6): 2098-111.
[http://dx.doi.org/10.1002/jcb.24084] [PMID: 22298343]
[31]
Kovacs B, Lumayag S, Cowan C, Xu S. MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011; 52(7): 4402-9.
[http://dx.doi.org/10.1167/iovs.10-6879] [PMID: 21498619]
[32]
Chen Q, Qiu F, Zhou K, et al. Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα. Diabetes 2017; 66(6): 1671-82.
[http://dx.doi.org/10.2337/db16-1246] [PMID: 28270521]
[33]
Qiu F, Tong H, Wang Y, Tao J, Wang H, Chen L. Inhibition of miR-21-5p suppresses high glucose-induced proliferation and angiogenesis of human retinal microvascular endothelial cells by the regulation of AKT and ERK pathways via maspin. Biosci Biotechnol Biochem 2018; 82(8): 1366-76.
[http://dx.doi.org/10.1080/09168451.2018.1459179] [PMID: 29658404]
[34]
Haque R, Iuvone PM, He L, et al. The MicroRNA-21 signaling pathway is involved in prorenin receptor (PRR) -induced VEGF expression in ARPE-19 cells under a hyperglycemic condition. Mol Vis 2017; 23: 251-62.
[PMID: 28465657]
[35]
Gutsaeva DR, Thounaojam M, Rajpurohit S, et al. STAT3-mediated activation of miR-21 is involved in down-regulation of TIMP3 and neovascularization in the ischemic retina. Oncotarget 2017; 8(61): 103568-80.
[http://dx.doi.org/10.18632/oncotarget.21592] [PMID: 29262585]
[36]
Zhang Y, Sun X, Icli B, Feinberg MW. Emerging Roles for MicroRNAs in Diabetic Microvascular Disease: Novel Targets for Therapy. Endocr Rev 2017; 38(2): 145-68.
[http://dx.doi.org/10.1210/er.2016-1122] [PMID: 28323921]
[37]
Sabatel C, Malvaux L, Bovy N, et al. MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells. PLoS ONE 2011; 10(2)e16979
[http://dx.doi.org/10.1371/journal.pone.0016979]]
[38]
Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010; 285(23): 17442-52.
[http://dx.doi.org/10.1074/jbc.M110.107821] [PMID: 20353945]
[39]
Wang J, Chen J, Sen S. MicroRNA as Biomarkers and Diagnostics. J Cell Physiol 2016; 231(1): 25-30.
[http://dx.doi.org/10.1002/jcp.25056] [PMID: 26031493]
[40]
Qing S, Yuan S, Yun C, et al. Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell Physiol Biochem 2014; 34(5): 1733-40.
[http://dx.doi.org/10.1159/000366374] [PMID: 25427542]
[41]
Jiang Q, Lyu X-M, Yuan Y, Wang L. Plasma miR-21 expression: an indicator for the severity of Type 2 diabetes with diabetic retinopathy. Biosci Rep 2017; 37(2)BSR20160589
[http://dx.doi.org/10.1042/BSR20160589] [PMID: 28108673]
[42]
Mazzeo A, Lopatina T, Gai C, Trento M, Porta M, Beltramo E. Functional analysis of miR-21-3p, miR-30b-5p and miR-150-5p shuttled by extracellular vesicles from diabetic subjects reveals their association with diabetic retinopathy. Exp Eye Res 2019; 184: 56-63.
[http://dx.doi.org/10.1016/j.exer.2019.04.015] [PMID: 31002820]
[43]
Raptis AE, Viberti G. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2001; 109(Suppl. 2): S424-37.
[http://dx.doi.org/10.1055/s-2001-18600] [PMID: 11460589]
[44]
Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic nephropathy: diagnosis and treatment. Nat Rev Endocrinol 2013; 9(12): 713-23.
[http://dx.doi.org/10.1038/nrendo.2013.184] [PMID: 24100266]
[45]
Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42(5): 1050-65.
[http://dx.doi.org/10.1161/01.HYP.0000102971.85504.7c] [PMID: 14604997]
[46]
Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295-306.
[http://dx.doi.org/10.1056/NEJMoa1811744] [PMID: 30990260]
[47]
Wang LP, Gao YZ, Song B, et al. MicroRNAs in the Progress of Diabetic Nephropathy: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2019.20193513179
[http://dx.doi.org/10.1155/2019/3513179] [PMID: 30984273]
[48]
Lai JY, Luo J, O’Connor C, et al. MicroRNA-21 in glomerular injury. J Am Soc Nephrol 2015; 26(4): 805-16.
[http://dx.doi.org/10.1681/ASN.2013121274] [PMID: 25145934]
[49]
Gomez IG, MacKenna DA, Johnson BG, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 2015; 125(1): 141-56.
[http://dx.doi.org/10.1172/JCI75852] [PMID: 25415439]
[50]
Kölling M, Kaucsar T, Schauerte C, et al. Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Mol Ther 2017; 25(1): 165-80.
[http://dx.doi.org/10.1016/j.ymthe.2016.08.001] [PMID: 28129112]
[51]
McClelland AD, Herman-Edelstein M, Komers R, et al. miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond) 2015; 129(12): 1237-49.
[http://dx.doi.org/10.1042/CS20150427] [PMID: 26415649]
[52]
Dey N, Das F, Mariappan MM, et al. MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem 2011; 286(29): 25586-603.
[http://dx.doi.org/10.1074/jbc.M110.208066] [PMID: 21613227]
[53]
Lin L, Gan H, Zhang H, et al. MicroRNA 21 inhibits SMAD7 expression through a target sequence in the 3′ untranslated region and inhibits proliferation of renal tubular epithelial cells. Mol Med Rep 2014; 10(2): 707-12.
[http://dx.doi.org/10.3892/mmr.2014.2312] [PMID: 24913635]
[54]
Wang J-Y, Gao Y-B, Zhang N, et al. miR-21 overexpression enhances TGF-β1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 2014; 392(1-2): 163-72.
[http://dx.doi.org/10.1016/j.mce.2014.05.018] [PMID: 24887517]
[55]
Zhong X, Chung ACK, Chen HY, et al. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56(3): 663-74.
[http://dx.doi.org/10.1007/s00125-012-2804-x] [PMID: 23292313]
[56]
Kantharidis P, Wang B, Carew RM, Lan HY. Diabetes complications: the microRNA perspective. Diabetes 2011; 60(7): 1832-7.
[http://dx.doi.org/10.2337/db11-0082] [PMID: 21709278]
[57]
Chen X, Zhao L, Xing Y, Lin B. Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression. Biomed Pharmacother 2018; 108: 7-14.
[http://dx.doi.org/10.1016/j.biopha.2018.09.007] [PMID: 30212710]
[58]
Fiorentino L, Cavalera M, Mavilio M, et al. Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs. Acta Diabetol 2013; 50(6): 965-9.
[http://dx.doi.org/10.1007/s00592-013-0492-8] [PMID: 23797704]
[59]
Badal SS, Danesh FR. Diabetic Nephropathy: Emerging Biomarkers for Risk Assessment. Diabetes 2015; 64(9): 3063-5.
[http://dx.doi.org/10.2337/db15-0738] [PMID: 26294427]
[60]
Chen C, Lu C, Qian Y, et al. Urinary miR-21 as a potential biomarker of hypertensive kidney injury and fibrosis Scientific Reports [Internet] 2017 Dec [cited 2019 Sep 29];7(1) Available from: http://www.nature.com/articles/s41598-017-18175-3
[http://dx.doi.org/10.1038/s41598-017-18175-3]
[61]
Wang J, Duan L, Tian L, et al. Serum miR-21 may be a Potential Diagnostic Biomarker for Diabetic Nephropathy. Exp Clin Endocrinol Diabetes 2016; 124(7): 417-23.
[PMID: 26575121]
[62]
Zhang L, He S, Yang F, et al. Hyperoside ameliorates glomerulosclerosis in diabetic nephropathy by downregulating miR-21. Can J Physiol Pharmacol 2016; 94(12): 1249-56.
[http://dx.doi.org/10.1139/cjpp-2016-0066] [PMID: 27704873]
[63]
Diabetic neuropathy. Nature Reviews Disease Primers 2019; 5(1) Available from: http://www.nature.com/articles/s41572-019-0097-9
[64]
Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328(23): 1676-85.
[http://dx.doi.org/10.1056/NEJM199306103282306] [PMID: 8487827]
[65]
Simeoli R, Fierabracci A. Insights into the Role of MicroRNAs in the Onset and Development of Diabetic Neuropathy. Int J Mol Sci 2019; 20(18): 4627.
[http://dx.doi.org/10.3390/ijms20184627] [PMID: 31540445]
[66]
Karl F, Grießhammer A, Üçeyler N, Sommer C. Differential Impact of miR-21 on Pain and Associated Affective and Cognitive Behavior after Spared Nerve Injury in B7-H1 ko Mouse. Front Mol Neurosci 2017; 10: 219.
[http://dx.doi.org/10.3389/fnmol.2017.00219] [PMID: 28744199]
[67]
Shilo S, Roy S, Khanna S, Sen CK. MicroRNA in cutaneous wound healing: a new paradigm. DNA Cell Biol 2007; 26(4): 227-37.
[http://dx.doi.org/10.1089/dna.2006.0568] [PMID: 17465889]
[68]
Madhyastha R, Madhyastha H, Nakajima Y, Omura S, Maruyama M. MicroRNA signature in diabetic wound healing: promotive role of miR-21 in fibroblast migration. Int Wound J 2012; 9(4): 355-61.
[http://dx.doi.org/10.1111/j.1742-481X.2011.00890.x] [PMID: 22067035]
[69]
Bitar MS, Labbad ZN. Transforming growth factor-β and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J Surg Res 1996; 61(1): 113-9.
[http://dx.doi.org/10.1006/jsre.1996.0090] [PMID: 8769952]
[70]
Broadley KN, Aquino AM, Hicks B, et al. The diabetic rat as an impaired wound healing model: stimulatory effects of transforming growth factor-beta and basic fibroblast growth factor. Biotechnol Ther 1990; 19891(1): 55-68.
[PMID: 2562644]
[71]
Chesnoy S, Lee P-Y, Huang L. Intradermal injection of transforming growth factor-beta1 gene enhances wound healing in genetically diabetic mice. Pharm Res 2003; 20(3): 345-50.
[http://dx.doi.org/10.1023/A:1022635600479] [PMID: 12669952]
[72]
Liang L, Stone RC, Stojadinovic O, et al. Integrative analysis of miRNA and mRNA paired expression profiling of primary fibroblast derived from diabetic foot ulcers reveals multiple impaired cellular functions. Wound Repair Regen 2016; 24(6): 943-53.
[http://dx.doi.org/10.1111/wrr.12470] [PMID: 27607190]
[73]
Nonaka CKV, Macêdo CT, Cavalcante BRR, et al. Circulating miRNAs as Potential Biomarkers Associated with Cardiac Remodeling and Fibrosis in Chagas Disease Cardiomyopathy. Int J Mol Sci 2019; 20(16): 4064.
[http://dx.doi.org/10.3390/ijms20164064] [PMID: 31434314]
[74]
Olivieri F, Spazzafumo L, Bonafè M, et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget 2015; 6(34): 35372-82.
[http://dx.doi.org/10.18632/oncotarget.6164] [PMID: 26498351]
[75]
Zhang Z, Peng H, Chen J, et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 2009; 583(12): 2009-14.
[http://dx.doi.org/10.1016/j.febslet.2009.05.021] [PMID: 19450585]
[76]
Madhyastha R, Madhyastha H, Pengjam Y, Nakajima Y, Omura S, Maruyama M. NFkappaB activation is essential for miR-21 induction by TGFβ1 in high glucose conditions. Biochem Biophys Res Commun 2014; 451(4): 615-21.
[http://dx.doi.org/10.1016/j.bbrc.2014.08.035] [PMID: 25130469]

Rights & Permissions Print Cite
Article Metrics
73
2
Wayfinder Image
TIMBC 2025
© 2025 Bentham Science Publishers | Privacy Policy